Citadel Advisors
IGC icon

Citadel Advisors’s IGC Pharma IGC Stock Holding History

Citadel Advisors’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-600
Closed -$202 – 14979
2024
Q4 		$202 Sell
600
-600
-50% -$225 ﹤0.01% 14368
2024
Q3 		$512 Buy
1,200
+400
+50% +$160 ﹤0.01% 14005
2024
Q2 		$347 Buy
+800
New +$398 ﹤0.01% 14016
2024
Q1 		– Sell
-2,600
Closed -$728 – 14982
2023
Q4 		$728 Hold
2,600
– – ﹤0.01% 13951
2023
Q3 		$934 Buy
2,600
+100
+4% +$36 ﹤0.01% 13951
2023
Q2 		$779 Hold
2,500
– – ﹤0.01% 14048
2023
Q1 		$849 Sell
2,500
-24,900
-91% -$9.34K ﹤0.01% 14409
2022
Q4 		$8.72K Sell
27,400
-500
-2% -$204 ﹤0.01% 13734
2022
Q3 		$12K Buy
27,900
+700
+3% +$373 ﹤0.01% 12226
2022
Q2 		$14K Sell
27,200
-8,000
-23% -$5.05K ﹤0.01% 12512
2022
Q1 		$33K Sell
35,200
-19,700
-36% -$19.1K ﹤0.01% 13052
2021
Q4 		$54K Sell
54,900
-24,600
-31% -$33K ﹤0.01% 13208
2021
Q3 		$118K Buy
79,500
+9,300
+13% +$15K ﹤0.01% 12664
2021
Q2 		$115K Sell
70,200
-12,900
-16% -$19.7K ﹤0.01% 12787
2021
Q1 		$149K Buy
83,100
+41,400
+99% +$75.2K ﹤0.01% 12040
2020
Q4 		$65K Buy
41,700
+26,500
+174% +$39.2K ﹤0.01% 10461
2020
Q3 		$16K Buy
+15,200
New +$15.4K ﹤0.01% 9895

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's IGC Position: Q1 2026 in Review

Citadel Advisors sold out of IGC Pharma (IGC) in Q1 2026, closing a stake of 277,594 shares — an estimated $78.1K sold.

Citadel Advisors first reported a position in IGC in Q4 2013 and held it in 30 quarters. The position peaked at $262K in Q3 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

  • Citadel Advisors reported no remaining IGC Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 277,594 IGC Pharma shares in Q1 2026, an estimated $78.1K.
  • Citadel Advisors first reported a position in IGC Pharma in Q4 2013 and held it in 30 quarters.
  • Citadel Advisors's IGC Pharma position peaked at $262K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.